Thailand Endometrial Receptivity Array (ERA) Test: Process, Cost, and Candidate Analysis

What is the ERA Test – A Direct Answer

The ERA (Endometrial Receptivity Array) test is a molecular biology diagnostic method that analyzes the expression profile of 248 genes in endometrial tissue to determine whether the endometrium is in the receptive state and whether the optimal transfer time is displaced.

This test answers three core questions at the genetic level:

• Whether the current endometrium is in a receptive state
• Whether the implantation window is advanced or delayed
• On which day the optimal transfer time should be

Test results are classified into three categories: Receptive, Non-receptive, and Displaced Implantation Window. For patients with a displaced implantation window, adjusting the embryo transfer time according to the direction of displacement can significantly improve pregnancy outcomes.

Why Does Implantation Window Displacement Occur?

The causes of implantation window displacement are not fully understood. Clinical observations have identified the following factors associated with it:

• Endometrial factors: Thin endometrium, chronic endometritis, intrauterine adhesions, endometrial polyps or fibroids affecting endometrial receptivity
• Hormonal abnormalities: Abnormal estrogen or progesterone levels affecting endometrial transformation
• Genetic factors: Some patients have gene polymorphisms related to endometrial receptivity
• Age factor: The incidence of implantation window displacement is relatively higher in older women (≥38 years)
• Previous surgical history: Multiple intrauterine surgical procedures may affect endometrial responsiveness
• Unexplained: Some patients have no clear cause but still exhibit implantation window displacement

Clinical data shows that among patients with recurrent implantation failure, the incidence of implantation window displacement is approximately 20%-30%. This means that about 1 in 4 patients with recurrent implantation failure could potentially improve by adjusting the transfer time.

Physician's Perspective: Clinical Value and Limitations of ERA

From a reproductive medicine standpoint, the value of the ERA test lies in providing an actionable direction for recurrent implantation failure. When routine examinations (hysteroscopy, immunology, coagulation function, etc.) reveal no abnormalities, the ERA test can help identify the potential cause of implantation window displacement.

Candidates Suitable for ERA Testing

• Patients who have undergone ≥2 transfers of good quality embryos (blastocysts) without pregnancy
• Unexplained recurrent implantation failure
• History of previous implantation window displacement
• Thin endometrium or poor response to hormones

Candidates Not Routinely Recommended for ERA Testing

• Patients undergoing their first transfer
• Patients with a known clear implantation window and successful transfer history
• Patients with untreated uterine pathology (e.g., large polyps, submucosal fibroids)
• Implantation failure due to poor embryo quality or chromosomal abnormalities

The clinical value needs to be viewed objectively. The positive predictive value of the ERA test is approximately 70%-80%, meaning that some patients will still fail to implant after adjustment, as embryo implantation is a multifactorial process. The ERA test only addresses the "timing" issue and does not resolve problems related to embryo quality, uterine environment, or immune factors.

Actual Process of ERA Testing in Thailand

In Thailand, the ERA testing process involves the following steps:

Detailed Explanation

Cycle Preparation: There are two protocols. The hormone replacement cycle uses exogenous estrogen and progesterone to mimic the natural cycle; the natural cycle monitors follicular development and the LH surge, performing the biopsy at a specific time point after ovulation. Thai fertility centers often prefer the hormone replacement cycle due to its controllable timing.

Endometrial Biopsy: A thin, flexible sampling catheter is inserted through the cervix into the uterine cavity to aspirate a small amount of endometrial tissue. The entire procedure takes about 10 minutes, requires no anesthesia, and some patients may experience mild bloating or discomfort.

Sample Shipment: Most fertility centers in Thailand collaborate with the Igenomix laboratory in Spain, requiring frozen transport of the sample. Some centers also offer local or regional laboratory testing services.

Report Time: It takes approximately 10-14 days from sample shipment to receiving the report, depending on the laboratory schedule and logistics.

Factors Influencing Cost

The cost of the ERA test in Thailand is influenced by the following factors:

Total cost range: The total cost for the ERA test in Thailand is approximately 60,000-100,000 THB (about 12,000-20,000 RMB), excluding embryo transfer costs. The cost difference mainly stems from hospital pricing strategies and whether imported test kits are used.

Easily Overlooked Details

• The biopsy time point must be precise: The accuracy of the ERA test is highly dependent on the biopsy timing. If the biopsy time point is incorrect (e.g., miscalculation of progesterone exposure days), the test results may be inaccurate. It is recommended to perform the biopsy on day 5 (120 hours) after progesterone exposure, with a margin of error within ±2 hours.
• A complete mock cycle is required: The ERA test cannot be performed in the same cycle as the transfer; a separate mock cycle is needed. This means an additional cycle time of about 1 month.
• Rest is needed after biopsy: It is recommended to rest for 1 day after the endometrial biopsy, avoiding strenuous exercise and sexual intercourse. Some patients may experience slight vaginal bleeding, which is normal.
• Validity of test results: ERA test results are theoretically valid for 1-2 years, but retesting may be necessary if the patient develops significant endometrial pathology, has surgery, or experiences marked changes in hormone levels.
• Embryo quality remains key: The ERA test cannot replace embryo quality assessment. If the embryo itself has chromosomal abnormalities or poor developmental potential, implantation will not occur even with accurate transfer timing.
• Difference between local testing in Thailand and sending to Spain: Some Thai fertility centers send samples to the Igenomix headquarters in Spain for testing, while others use local laboratories. Sending to Spain results in a longer testing period (including logistics time) but offers higher standardization of results.

Common Pitfalls to Avoid

• Assuming the ERA test can solve all implantation problems: The ERA test only addresses the issue of "implantation window displacement." There are many causes of implantation failure, including embryo chromosomal abnormalities, intrauterine adhesions, chronic endometritis, immune factors, and coagulation disorders. The ERA test cannot replace other investigations like hysteroscopy or immunological testing.
• Proceeding directly to ERA without ruling out uterine pathology: If uterine polyps, adhesions, endometritis, or other lesions are present, these should be treated first before assessing the need for an ERA test. Uterine pathology affects endometrial receptivity, making the ERA test of limited value at that point.
• Using the ERA test as routine screening: For patients undergoing their first transfer or those with a history of successful transfer, the necessity of the ERA test is very low. Blindly performing the ERA test not only increases costs but also delays the treatment cycle.
• Ignoring the consistency of the cycle protocol: The endometrial preparation protocol (hormone replacement or natural cycle) used in the ERA test cycle should be consistent with the subsequent transfer cycle. If the test cycle uses a hormone replacement protocol, the transfer cycle should ideally use the same protocol; otherwise, the test results may not be applicable.
• Overinterpreting the test results: ERA test results are categorized as receptive, non-receptive, or displaced implantation window. Some patients may fall into a "borderline" state, where result interpretation requires clinical experience. It is recommended that an experienced reproductive specialist interpret the report, rather than making a self-assessment.
• Neglecting differences between testing standards in Thailand and domestic standards: The ERA testing standards used in Thailand are largely consistent with those in Europe and the United States, but subtle differences may exist between different laboratories. It is advisable to have the test and result interpretation done at the same laboratory.

Frequently Asked Questions